Valacyclovir News and Research

RSS
Valacyclovir is a substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals.
Shingles raises the risk for heart attack and stroke

Shingles raises the risk for heart attack and stroke

Study compares medications for treatment of persons with recurrent genital herpes

Study compares medications for treatment of persons with recurrent genital herpes

NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

Common herpes drug Valacyclovir decreases HIV-1 levels

Common herpes drug Valacyclovir decreases HIV-1 levels

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex fourth quarter net loss increases to $7.0 million

Dr. Reddy’s third quarter consolidated revenues increase 10% to $424 million

Dr. Reddy’s third quarter consolidated revenues increase 10% to $424 million

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles